Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/s41577-020-00471-1 http://scihub22266oqcxt.onion/10.1038/s41577-020-00471-1 33139888!7605490!33139888     free     free     free Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Nat+Rev+Immunol 2020 ; 20 (12): 727-738 Nephropedia Template TP {{tp|p=33139888|t=2020. Measuring immunity to SARS-CoV-2 infection: comparing assays and animal models |pdf=|usr=}}{{33139888}} gab.com Text Measuring immunity to SARS-CoV-2 infection: comparing assays and animal models JO: Nat Rev Immunol http://www.kidney.de/pget.php?&tw=1&pmid=33139888 #FOAvip The rapid scale-up of research on coronavirus disease 2019 (COVID-19) has spawned a large number of potential vaccines and immunotherapies, accompanied by a commensurately large number of in vitro assays and in vivo models to measure their effectiveness. These assays broadly have the same end-goal - to predict the clinical efficacy of prophylactic and therapeutic interventions in humans. However, the apparent potency of different interventions can vary considerably between assays and animal models, leading to very different predictions of clinical efficacy. Complete harmonization of experimental methods may be intractable at the current pace of research. However, here we analyse a selection of existing assays for measuring antibody-mediated virus neutralization and animal models of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and provide a framework for comparing results between studies and reconciling observed differences in the effects of interventions. Finally, we propose how we might optimize these assays for better comparison of results from in vitro and animal studies to accelerate progress. Twit Text FOAVip Measuring immunity to SARS-CoV-2 infection: comparing assays and animal models ????Nat Rev Immunol http://www.kidney.de/pget.php?&tw=1&pmid=33139888 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33139888 #FOAvip English Wikipedia <ref>{{Cite pmid|33139888}}</ref> Measuring immunity to SARS-CoV-2 infection: comparing assays and animal models #MMPMID33139888 Khoury DS; Wheatley AK; Ramuta MD; Reynaldi A; Cromer D; Subbarao K; O'Connor DH; Kent SJ; Davenport MP Nat Rev Immunol 2020[Dec]; 20 (12): 727-738 PMID33139888show ga The rapid scale-up of research on coronavirus disease 2019 (COVID-19) has spawned a large number of potential vaccines and immunotherapies, accompanied by a commensurately large number of in vitro assays and in vivo models to measure their effectiveness. These assays broadly have the same end-goal - to predict the clinical efficacy of prophylactic and therapeutic interventions in humans. However, the apparent potency of different interventions can vary considerably between assays and animal models, leading to very different predictions of clinical efficacy. Complete harmonization of experimental methods may be intractable at the current pace of research. However, here we analyse a selection of existing assays for measuring antibody-mediated virus neutralization and animal models of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and provide a framework for comparing results between studies and reconciling observed differences in the effects of interventions. Finally, we propose how we might optimize these assays for better comparison of results from in vitro and animal studies to accelerate progress. |Animals[MESH] |COVID-19 Drug Treatment[MESH] |COVID-19 Serological Testing/*methods[MESH] |COVID-19/*immunology/prevention & control[MESH] |Disease Models, Animal[MESH] |Humans[MESH] |Immunoassay/*methods[MESH] |Neutralization Tests[MESH]Measuring immunity to SARS-CoV-2 infection: comparing assays and anima(epmc).pdf DeepDyve Pubget Overpricing